GC Cell, founded to specialize in cell therapy, obtained approval for its developed Immunecell-LC as a liver cancer immunotherapy agent in 2007. Immunecell-LC has now finished third-phase clinical trials on liver cancer and brain tumors (glioblastoma/GBM), and is tailed by studies, published in SCI-level journals, on its efficacy in treating liver cancer, brain tumors, and pancreatic cancer (researcher-conducted clinical trial). The company is now researching and developing CAR-T, a next-generation cell immunotherapy agent, and, in partnership with ToolGen, a T-cell-based next-generation cancer immunotherapy agent with greater performance.
Focus Areas
Notable Investments
